• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症患者冠状动脉支架愈合——光学相干断层扫描视角

Coronary Stent Healing in Cancer Patients-An Optical Coherence Tomography Perspective.

作者信息

Aziz Moez Karim, Herrmann Joerg, Marmagkiolis Konstantinos, Balanescu Dinu Valentin, Donisan Teodora, Pushparaji Bala, Lin Heather Y, Tomakin Gerryross, Hoyt Taylor, Pham Martin, Dijkstra Jouke, Cilingiroglu Mehmet, Lopez-Mattei Juan, Zaha Vlad, Anderson H Vernon, Feldman Marc D, Molony Donald A, Iliescu Cezar A

机构信息

Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, United States.

出版信息

Front Cardiovasc Med. 2021 Jun 7;8:665303. doi: 10.3389/fcvm.2021.665303. eCollection 2021.

DOI:10.3389/fcvm.2021.665303
PMID:34164440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8215158/
Abstract

This study assessed stent healing patterns and cardiovascular outcomes by optical coherence tomography (OCT) in cancer patients after drug-eluting stent (DES) placement. Cancer treatment, owing to its cytotoxic and antiproliferative effects, could delay stent healing and increase stent thrombosis risk, especially when dual antiplatelet therapy (DAPT) is discontinued early for oncological treatment. OCT can assess stent endothelialization and other healing parameters, which may provide clinical guidance in these challenging scenarios. This single-center retrospective study enrolled all cancer patients who underwent OCT for assessment of vascular healing patterns after prior DES placement from November 2009 to November 2018. Primary study endpoints were stent healing parameters, including stent coverage, apposition, degree of expansion, neointimal hyperplasia heterogeneity, in-stent restenosis, stent thrombosis, and overall survival (OS). A total of 67 patients were included in this study. Mean time between DES placement and OCT evaluation was 154 ± 82 days. Stent healing matched published values for DES in non-cancer patients ( ≥ 0.063). At 1 year, the OS was 86% (95% confidence interval [CI]: 78-96%) with 0% incidence of acute coronary syndrome. Advanced cancers and active chemotherapies were associated with inferior OS ( = 0.024, hazard ratio [HR]: 3.50, 95% CI: 1.18-10.42 and = 0.026, HR: 2.65, 95% CI: 1.13-6.22, respectively), while stent healing parameters were unassociated with OS. Forty-one patients (61%) had DAPT duration ≤6 months. Stent healing of contemporary DES appears similar in cancer and non-cancer patients. Cardiovascular risk of cancer patients after DES placement can be managed to facilitate timely cancer therapies, as the underlying malignancy and active chemotherapy ultimately determine survival.

摘要

本研究通过光学相干断层扫描(OCT)评估了癌症患者药物洗脱支架(DES)置入后的支架愈合模式和心血管结局。由于癌症治疗具有细胞毒性和抗增殖作用,可能会延迟支架愈合并增加支架血栓形成风险,尤其是在为进行肿瘤治疗而提前停用双联抗血小板治疗(DAPT)时。OCT可评估支架内皮化及其他愈合参数,这可能为这些具有挑战性的情况提供临床指导。这项单中心回顾性研究纳入了2009年11月至2018年11月期间所有接受过OCT以评估既往DES置入后血管愈合模式的癌症患者。主要研究终点为支架愈合参数,包括支架覆盖率、贴壁情况、扩张程度、新生内膜增生异质性、支架内再狭窄、支架血栓形成及总生存期(OS)。本研究共纳入67例患者。DES置入与OCT评估之间的平均时间为154±82天。支架愈合情况与非癌症患者DES的已发表值相符(≥0.063)。1年时,OS为86%(95%置信区间[CI]:78 - 96%),急性冠状动脉综合征发生率为0%。晚期癌症和积极的化疗与较差的OS相关(分别为P = 0.024,风险比[HR]:3.50,95%CI:1.18 - 10.42;P = 0.026,HR:2.65,95%CI:1.13 - 6.22),而支架愈合参数与OS无关。41例患者(61%)的DAPT持续时间≤6个月。当代DES在癌症患者和非癌症患者中的支架愈合情况似乎相似。DES置入后癌症患者的心血管风险可得到控制,以便及时进行癌症治疗,因为潜在的恶性肿瘤和积极的化疗最终决定生存情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/347d9f173abb/fcvm-08-665303-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/449d2224af5d/fcvm-08-665303-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/65fb0b2f849f/fcvm-08-665303-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/f6a5db7f456a/fcvm-08-665303-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/714bd24d8f6b/fcvm-08-665303-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/28748338bf08/fcvm-08-665303-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/347d9f173abb/fcvm-08-665303-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/449d2224af5d/fcvm-08-665303-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/65fb0b2f849f/fcvm-08-665303-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/f6a5db7f456a/fcvm-08-665303-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/714bd24d8f6b/fcvm-08-665303-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/28748338bf08/fcvm-08-665303-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6f/8215158/347d9f173abb/fcvm-08-665303-g0006.jpg

相似文献

1
Coronary Stent Healing in Cancer Patients-An Optical Coherence Tomography Perspective.癌症患者冠状动脉支架愈合——光学相干断层扫描视角
Front Cardiovasc Med. 2021 Jun 7;8:665303. doi: 10.3389/fcvm.2021.665303. eCollection 2021.
2
"Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).复杂临床场景下的“点亮光明”:光学相干断层扫描指导下的冠心病癌症患者抗血小板治疗停药(PROTECT-OCT注册研究)
Am Heart J. 2017 Dec;194:83-91. doi: 10.1016/j.ahj.2017.08.015. Epub 2017 Aug 23.
3
A prospective, multicenter, randomized OCT study of early neointimal condition at first and second months after BuMA Supreme stent versus XIENCE stent implantation in high-bleeding-risk coronary artery disease patients: study protocol for a randomized controlled trial.前瞻性、多中心、随机 OCT 研究:高出血风险冠状动脉疾病患者使用 BuMA Supreme 支架与 XIENCE 支架植入后第一个和第二个月的早期新生内膜情况:一项随机对照试验研究方案。
Trials. 2019 Jun 7;20(1):335. doi: 10.1186/s13063-019-3361-0.
4
First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).首例人体生物可吸收聚合物涂层依维莫司洗脱支架的评估:DESOLVE I 试验(载有依维莫司和生物可吸收聚合物的 DES 治疗原发性冠状动脉病变患者)的影像学和临床结果。
JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.
5
Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation.OISTER 试验的原理和研究设计:非 ST 段抬高型急性冠状动脉综合征患者支架小梁再内皮化的光学相干断层成像评估——对比 intrEpide tRapidil 洗脱支架与紫杉醇药物洗脱支架植入。
J Cardiovasc Med (Hagerstown). 2010 Jul;11(7):536-43. doi: 10.2459/JCM.0b013e32833499c4.
6
A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.一项前瞻性随机研究,使用光学相干断层扫描评估冠状动脉依维莫司洗脱支架与紫杉醇洗脱球囊后扩张的金属裸支架在植入后 6 个月时的内皮覆盖和新生内膜增殖情况(OCTOPUS 试验):原理、设计和方法。
EuroIntervention. 2011 May;7 Suppl K:K93-9. doi: 10.4244/EIJV7SKA16.
7
Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.光学相干断层成像术评价依维莫司洗脱支架置入后 3 个月的新生内膜覆盖率:ENDEAVOR OCT 试验。
JACC Cardiovasc Interv. 2009 Dec;2(12):1240-7. doi: 10.1016/j.jcin.2009.10.006.
8
Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study.使用Angiolite®药物洗脱支架经皮冠状动脉介入治疗后3个月和6个月的光学相干断层扫描监测:ANCHOR研究。
Catheter Cardiovasc Interv. 2018 Feb 15;91(3):435-443. doi: 10.1002/ccd.27189. Epub 2017 Jul 14.
9
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.双联抗血小板治疗时间:2016 年 ACC/AHA 指南双联抗血小板治疗时间的聚焦更新:冠心病患者双联抗血小板治疗时间的临床实践指南——美国心脏病学会/美国心脏协会工作组报告。
J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39. doi: 10.1016/j.jacc.2016.03.512. Epub 2016 Mar 29.
10
OCT Analysis of Very Early Strut Coverage of the Synergy Stent in Non-ST Segment Elevation Acute Coronary Syndrome Patients.非ST段抬高型急性冠状动脉综合征患者中Synergy支架极早期支架小梁覆盖情况的光学相干断层扫描分析
J Invasive Cardiol. 2019 Jan;31(1):10-14. doi: 10.25270/jic/18.00274. Epub 2018 Nov 11.

引用本文的文献

1
Coronary Revascularization in Patients With Cancer.癌症患者的冠状动脉血运重建
Curr Treat Options Cardiovasc Med. 2023;25(6):143-158. doi: 10.1007/s11936-023-00982-9. Epub 2023 Apr 21.
2
Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review.心脏毒性的放射治疗机制:系统评价。
Int J Mol Sci. 2023 Mar 27;24(7):6272. doi: 10.3390/ijms24076272.
3
Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents.癌症患者使用裸金属支架与药物洗脱支架进行经皮冠状动脉介入治疗的比较。

本文引用的文献

1
2020 International Society of Hypertension global hypertension practice guidelines.2020年国际高血压学会全球高血压实践指南
J Hypertens. 2020 Jun;38(6):982-1004. doi: 10.1097/HJH.0000000000002453.
2
Drug-eluting coronary stents: insights from preclinical and pathology studies.药物洗脱冠状动脉支架:临床前和病理学研究的新视角。
Nat Rev Cardiol. 2020 Jan;17(1):37-51. doi: 10.1038/s41569-019-0234-x. Epub 2019 Jul 25.
3
Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy.
Front Cardiovasc Med. 2022 Oct 19;9:901431. doi: 10.3389/fcvm.2022.901431. eCollection 2022.
Onyx ONE 全球随机试验的原理和设计:支架置入后双联抗血小板治疗 1 个月的高出血风险患者的随机对照试验。
Am Heart J. 2019 Aug;214:134-141. doi: 10.1016/j.ahj.2019.04.017. Epub 2019 May 6.
4
Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials.关键癌症临床试验中心血管疾病患者的代表性。
Circulation. 2019 May 28;139(22):2594-2596. doi: 10.1161/CIRCULATIONAHA.118.039180. Epub 2019 Mar 18.
5
Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.药物洗脱支架置入后超过 1 年的双联抗血小板治疗时间的风险-获益特征与临床表现的关系。
Circ Cardiovasc Interv. 2019 Mar;12(3):e007541. doi: 10.1161/CIRCINTERVENTIONS.118.007541.
6
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.ACC/AHA 与 ESC 双重抗血小板治疗指南:JACC 指南比较。
J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2915-2931. doi: 10.1016/j.jacc.2018.09.057.
7
Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States.经皮冠状动脉介入治疗在癌症患者中的应用:美国的流行率和结局报告。
Eur Heart J. 2019 Jun 7;40(22):1790-1800. doi: 10.1093/eurheartj/ehy769.
8
The Newest Generation of Drug-eluting Stents and Beyond.最新一代药物洗脱支架及未来发展
Eur Cardiol. 2018 Aug;13(1):54-59. doi: 10.15420/ecr.2018:8:2.
9
A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial.随机比较 BuMA Supreme 支架和 XIENCE 支架在一个月和两个月随访时的愈合反应:PIONEER-II OCT 随机对照试验。
EuroIntervention. 2018 Dec 20;14(12):e1306-e1315. doi: 10.4244/EIJ-D-18-00461.
10
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis.氯吡格雷治疗对心血管和脑血管疾病患者死亡率和癌症的影响:一项基于患者水平的荟萃分析。
Circ Cardiovasc Interv. 2018 Jan;11(1):e005795. doi: 10.1161/CIRCINTERVENTIONS.117.005795.